Cantor Fitzgerald Issues Negative Outlook for BCAX Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for Bicara Therapeutics in a research note issued on Wednesday, May 14th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($2.11) per share for the year, down from their prior estimate of ($1.81). Cantor Fitzgerald has a “Overweight” rating and a $13.01 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Other analysts have also recently issued reports about the company. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright dropped their target price on Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Wells Fargo & Company started coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They issued an “underweight” rating and a $8.00 price target for the company. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $14.47 on Friday. Bicara Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $28.09. The firm’s 50-day simple moving average is $12.81 and its two-hundred day simple moving average is $15.31.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BCAX. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the fourth quarter valued at $25,000. CWM LLC bought a new position in Bicara Therapeutics during the 1st quarter valued at about $29,000. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $32,000. Finally, Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth approximately $33,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.